ARTICLE | Company News
Pfizer returns CP-609,754 to OSI
November 26, 2001 8:00 AM UTC
PFE returned to OSIP rights to CP-609,754, a farnesyl transferase inhibitor in Phase I testing for solid tumors. OSIP plans to develop the compound for bladder cancer, and will pay PFE royalties. ...